You are here

Translational Sciences Inc.

Company Information
Address
6725 E ROVEY AVE
PARADISE VALLEY, AZ 85253-4117
United States



Information

DUNS: 803592364

# of Employees: 0


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke

    Amount: $1,646,140.00

    Ischemic stroke is the second leading cause of death and disability worldwide. Tissue plasminogen activator (TPA), the only approved treatment for ischemic stroke, dissolves the culprit fibrin thrombu ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    Amount: $336,200.00

    Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reduc ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  3. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    Amount: $2,812,000.00

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal c ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  4. HLS Potent novel inhibitor of fibrinolytic hemorrhage

    Amount: $351,119.00

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest therapeutics that are of high programmatic interest HL Hemorrhage or bleeding is a serious or fatal c ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  5. Novel Methods for Dissolving Blood Clots

    Amount: $1,005,000.00

    DESCRIPTION provided by applicant Each year venous thromboembolism VTE affects up to million Americans and million people worldwide VTE patients have blood clots in the legs venous thrombo ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  6. Reducing Stroke by a Novel, Clot-dissolving Antibody

    Amount: $2,999,979.00

    DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and the primary cause of severe, long term disability. Each year 795,000 Americans have a stroke and the annual costs to ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  7. Novel Methods for Dissolving Blood Clots

    Amount: $1,519,440.00

    DESCRIPTION (provided by applicant): Each year, as many as 2 million Americans develop venous thromboembolism (VTE). VTEs are blood clots in the legs (venous thrombosis) that may travel to the lungs ( ...

    STTRPhase II2012Department of Health and Human Services National Institutes of Health
  8. Reducing Stroke by a Novel, Clot-dissolving Antibody

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and the primary cause of severe, long term disability. Each year 795,000 Americans have a stroke and the annual costs to ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  9. Novel Methods for Dissolving Blood Clots

    Amount: $167,685.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of death worldwide. Current therapies for cardiovascular disease are associated with partial success, restricted access ...

    STTRPhase I2010Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government